SCHEMBL214147

SCHEMBL214147

Cc1ccc(NC(=O)c2nc[nH]c2C(=O)Nc2nc3ccccc3n2C)c(C)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 4/20 0.51
ALDH1A1 P00352 7/20 0.49
MAPT P10636 6/20 0.49
KMT2A Q03164 6/20 0.49
KDM4E B2RXH2 5/20 0.49
MEN1 O00255 5/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
PDE11A Q9HCR9 1/20 0.48
PDE10A Q9Y233 1/20 0.48
NPC1 O15118 4/20 0.47
RAB9A P51151 4/20 0.47
NTRK1 P04629 1/20 0.47
HTT P42858 3/20 0.46
HSD17B10 Q99714 3/20 0.46
MAPK1 P28482 2/20 0.46
HPGD P15428 3/20 0.46
CYP1A2 P05177 1/20 0.46
LMNA P02545 2/20 0.45
TSHR P16473 2/20 0.45
USP2 O75604 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2759942 0.80 NPC1 (0.54) GAAALDH1A1MAPTKMT2AKDM4E
SCHEMBL2735321 0.79 NPC1 (0.54) GAAALDH1A1MAPTKMT2AKDM4E
SCHEMBL217146 0.77 MAPT (0.52) GAAALDH1A1MAPTKMT2AKDM4E
SCHEMBL4105577 0.76 GAA (0.55) GAAALDH1A1MAPTKMT2AKDM4E
SCHEMBL14222343 0.75 MAPT (0.50) GAAALDH1A1MAPTKMT2AKDM4E
SCHEMBL216648 0.75 KMT2A (0.57) GAAALDH1A1MAPTKMT2AKDM4E
SCHEMBL2735315 0.75 GAA (0.51) GAAALDH1A1MAPTKMT2AKDM4E
SCHEMBL213157 0.75 MAPT (0.80) GAAALDH1A1MAPTKMT2AKDM4E
SCHEMBL2735324 0.75 ALDH1A1 (0.56) GAAALDH1A1MAPTKMT2AKDM4E
SCHEMBL216597 0.74 MAPT (0.54) GAAALDH1A1MAPTKMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088767-B2 JAK-2 modulators and methods of use EXELIXIS, INC. (US) 2012-01-03 US claimed
US-20100136136-A1 JAK-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2010-06-03 US claimed
US-8088767-B2 JAK-2 modulators and methods of use EXELIXIS, INC. (US) 2012-01-03 US disclosed
US-20100136136-A1 JAK-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2010-06-03 US disclosed
WO-2008042282-A2 IMIDAZOLE-4, 5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS EXELIXIS, INC. (US) 2008-04-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100136136-A1 JAK-2 Modulators and Methods of Use JAK2, JAK1, JAK3 GAA 2375/4885ALDH1A1 4295/4885MAPT 2138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.